Donor lazaroid pretreatment improves viability of livers harvested from non-heart-beating rats.
BACKGROUND
Lazaroids are potent inhibitors of lipid peroxidation. Whether the compounds can benefit the liver procured from non-heart-beating donors (NHBDs) is unknown.


METHODS
Donor rats were pretreated with lazaroid U74006F (4.5 mg/kg) 1 hour before cardiac arrest, and transplantation was performed in the rats with donor cardiac arrest from 0 to 60, 100, 120, 140, and 160 minutes as lazaroid pretreated groups. The same number of liver transplantations were done in each paired control group without donor lazaroid pretreatment. Recipient survival rates, bile secretion, serum enzymes, and a lidocaine metabolism test were analyzed.


RESULTS
Donor lazaroid pretreatment significantly increased recipient 3-day survival rates in groups with 60, 100, and 120 minutes of warm ischemia and 7-day survival with 60 minutes of warm ischemia. Also, the pretreatment increased bile secretion and reduced serum aspartate aminotransferase and lactate dehydrogenase levels in the lazaroid-pretreated groups.


CONCLUSIONS
Donor U74006F pretreatment improves viability of livers procured from NHBDs.
Xu
H S
HS
Department of Surgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Stevenson
W C
WC
Pruett
T L
TL
Jones
R S
RS
D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001646:Bile / Q000378:metabolism; D006323:Heart Arrest; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008012:Lidocaine / Q000378:metabolism; D016031:Liver Transplantation; D008297:Male; D011281:Pregnatrienes / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014022:Tissue Survival / Q000187:drug effects
D011281:Pregnatrienes; D008012:Lidocaine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; C053355:tirilazad